CHANTIBODY

Serial Number 98125029
Registration 7472341
700

Registration Progress

Application Filed
Aug 9, 2023
Under Examination
Approved for Publication
May 28, 2024
Published for Opposition
May 28, 2024
Registered
Aug 13, 2024

Trademark Image

CHANTIBODY

Basic Information

Serial Number
98125029
Registration Number
7472341
Filing Date
August 9, 2023
Registration Date
August 13, 2024
Published for Opposition
May 28, 2024
Drawing Code
3

Status Summary

Current Status
Active
Status Code
700
Status Date
Aug 13, 2024
Registration
Registered
Classes
042

Rights Holder

Chantibody Therapeutics Inc.

03
Address
1440 OBRIEN DR STE C MENLO PARK,
California, CA 940251432

Ownership History

Chantibody Therapeutics Inc.

Original Applicant
03
California, CA

Chantibody Therapeutics Inc.

Owner at Publication
03
California, CA

Chantibody Therapeutics Inc.

Original Registrant
03
California, CA

Legal Representation

Attorney
Alexander Ruzzier

USPTO Deadlines

Next Deadline
1685 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20240813)
Due Date
August 13, 2030
Grace Period Ends
February 13, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

10 events
Date Code Type Description Documents
Aug 13, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Aug 13, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
May 28, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
May 28, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
May 8, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Apr 22, 2024 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Apr 9, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 12, 2023 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Sep 10, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Aug 12, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
Research and development services performed for others in the fields of drug discovery, drug discovery products, pharmaceuticals, medicinal diagnostics, and biological products; Laboratory research and development services relating to the production of antibodies; Research and development services in the field of antibodies; Medical and Scientific research and development in the fields of cancer, immunological-inflammatory chronic conditions, tissue repair, biology, laboratory testing, biotechnology, biochemistry, and medicine; Research and product development services for others in the fields of cancer, immunological-inflammatory chronic conditions, tissue repair, biology, laboratory testing, biotechnology, biochemistry, and medicine; Providing information on the subject of scientific research in the fields of cancer, immunological-inflammatory chronic conditions, tissue repair, biology, laboratory testing, biotechnology, biochemistry, and medicine; Biotechnology research; Pharmaceutical research and development; Pharmaceutical research services; Scientific and technological services, namely, research and development in the field of discovery, design, and development of antigen-binding molecules, using artificial intelligence and other computer-aided computational techniques, and laboratory services relating to the aforesaid molecular discovery, design, and development
First Use Anywhere: Nov 5, 2022
First Use in Commerce: Nov 5, 2022

Additional Information

Design Mark
The mark consists of the literal element "CHANTIBODY" in stylized font along with a radial three-loop design element in the upper right corner.
Color Claim
Color is not claimed as a feature of the mark.
Translation
The wording "CHANTIBODY" has no meaning in a foreign language.

Classification

International Classes
042